On our screens:Stocks that buy back more than they dilute
Is the price fair?
What ABBV's price assumes
AbbVie trades at 70.3× earnings against 26.4× for the median Drug Manufacturers - General name, more expensive than its own group.
70.3
Trailing P/E · Drug Manufacturers - General median 26.4 · 2.67× the median: the market pays up for this one
- Price / sales
- 6.09
Price / sales · as of 2026-Q1
- Free cash flow yield
- 4.8%
Free cash flow yield · Drug Manufacturers - General median 5.7%
- Growth the price implies
- +6.3%
Growth the price implies · The price pays for +6.3% free cash flow growth a year for a decade; the business has delivered −9.8% a year over the last three.
Details›
- Healthcare median P/E362 names
- 29.9
- Drug Manufacturers - General median P/E16 names
- 26.4
- Free cash flow, trailing twelve months
- $18.2B
- Market capitalisation
- $382.5B
- 3-year revenue growth
- +4.8%
- 3-year free cash flow growth
- −9.8%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 110× today against a 20.8× median |
| 52-week range | $197.38 – $266.10 |
| Today | $248.83 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - General
The closest names by size in the same industry